On September 25, 2026, Mirum Pharmaceuticals announced the approval of its new investigational therapy, a strategic expansion that is expected to capture significant market share in the emerging therapeutic landscape. The approval positions the company to capitalize on the high unmet demand for this category, driving strong commercial growth potential and reinforcing its competitive footprint in the sector.